Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kathy Tolzien"'
Publikováno v:
Avicenna Journal of Medicine, Vol 01, Iss 01, Pp 12-17 (2011)
Purpose: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. Materials and Methods: CRPC patients who maximized their response to either doc
Externí odkaz:
https://doaj.org/article/7da2de9150f640a6818140361796f919
Autor:
Angel G. Galvez, Jacob D. Bitran, Timothy M. Lestingi, Andrew Meyer, Chadi Nabhan, Peter Cygan, Kathy Tolzien
Publikováno v:
Clinical Genitourinary Cancer. 12:100-105
Background Sorafenib promotes apoptosis through downstream pathways that can be deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy resistance in CRPC. Patients and Methods Eligible patients were those whose disease had pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f9317ac4dd96f5d19dd8b93336182e
https://doi.org/10.1016/j.clgc.2013.09.003
https://doi.org/10.1016/j.clgc.2013.09.003
Publikováno v:
Clinical Genitourinary Cancer. 12:27-32
Background We investigated the activity of lenalidomide, which has antiangiogenic, antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration-resistant prostate cancer (CRPC) patients. Patients Patients received 25 mg/d lenali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd06a5c4bf436a6407e8749d7beaa7f
https://doi.org/10.1016/j.clgc.2013.09.001
https://doi.org/10.1016/j.clgc.2013.09.001
Autor:
Kimberly Kruczek, Kathy Tolzien, Megan Ratterman, Timothy M. Lestingi, Suela Sulo, Chadi Nabhan
Publikováno v:
British Journal of Cancer
Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of temsirolimus, an mTOR inhibitor, in chemotherapy-naïve CRPC. Methods: In this ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b18164573dea7edaa5310714a1fc46
https://doi.org/10.1038/bjc.2013.530
https://doi.org/10.1038/bjc.2013.530
Publikováno v:
Avicenna Journal of Medicine, Vol 01, Iss 01, Pp 12-17 (2011)
Avicenna Journal of Medicine
Avicenna Journal of Medicine
Purpose: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. Materials and Methods: CRPC patients who maximized their response to either doc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199b1a428719240b1fc6e80807e5d52f
https://doi.org/10.4103/2231-0770.83718
https://doi.org/10.4103/2231-0770.83718
Autor:
Angel G. Galvez, Jacob D. Bitran, Kathy Tolzien, Steven Newman, Dean Tsarwhas, Chadi Nabhan, Susan K. Kelby, Timothy M. Lestingi
Publikováno v:
Urology. 74:665-671
Objectives To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive castration-resistant prostate cancer. Methods Eligible patients received erlotinib at 150 mg daily until disease progression. Toxicity was assessed ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3a168a9d1564047ca673e9d4e539e5
https://doi.org/10.1016/j.urology.2009.05.016
https://doi.org/10.1016/j.urology.2009.05.016
Autor:
Jacob D. Bitran, Merrill J. Egorin, Chadi Nabhan, Dana Villines, Jan H. Beumer, Kathy Tolzien, Tina V. Valdez, Susan M. Christner, Timothy M. Lestingi
Publikováno v:
British Journal of Cancer
Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients. Methods: Refractory CRPC patients were enrolled onto this 3+3 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b114ed6d014a69dd47869e60df7ff841
https://pubmed.ncbi.nlm.nih.gov/22805325
https://pubmed.ncbi.nlm.nih.gov/22805325
Publikováno v:
Clinical lymphoma, myelomaleukemia. 12(1)
Objective To evaluate the efficacy and toxicity of the combination of VRCD (velcade/rituximab/cyclophosphamide/dexamethasone) in chemotherapy-naive low-grade non-Hodgkin lymphoma or patients with transplantation-ineligible mantle cells. Methods The p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655bd68a26a99ebdac295bb91b2d83b5
https://pubmed.ncbi.nlm.nih.gov/21752745
https://pubmed.ncbi.nlm.nih.gov/21752745
Autor:
Kathy Tolzien, Angel G. Galvez, Wendy M. Dewey, Chadi Nabhan, Walter Fried, Nancy Davis, Susan Foss, Jacob D. Bitran, Parameswaran Venugopal
Publikováno v:
Cancer. 117(7)
BACKGROUND: Currently, no standard therapy exists for patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL) who are ineligible for transplantation or who have failed after bone marrow transplantation. The authors of this report investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a2acd69a01f1a4c0fc2655509a0864
https://pubmed.ncbi.nlm.nih.gov/21425150
https://pubmed.ncbi.nlm.nih.gov/21425150
Publikováno v:
Journal of chemotherapy (Florence, Italy). 21(4)
We sought to evaluate the safety and efficacy of docetaxel and oxaliplatin combination as first-line therapy for patients with stage IV or wet IIIB non small cell lung cancer. Patients received oxaliplatin at 85 mg/m2 intravenously over 2 hours on da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d37ff2c055c408ba1659f53f0acfef
https://pubmed.ncbi.nlm.nih.gov/19622464
https://pubmed.ncbi.nlm.nih.gov/19622464